Elemental Impurities (ICH Q3D)
ICH Q3D governs the control of elemental (metal) impurities in drug products — catalysts, reagents, equipment-derived metals, container leachables and excipient contaminants. It replaces the old non-specific heavy-metals limit test with a toxicologically grounded, risk-based framework built on permitted daily exposures for a defined set of elements, differentiated by route of administration. The output is not a single test but a documented risk assessment that justifies where control is and is not needed.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 22 LINKSICH Q3D replaced the non-specific heavy-metals test with PDE-based, route-differentiated limits and a documented risk assessment that sums every elemental source against the product's permitted daily exposure.
06 · QUALITY MATURITY — ELEMENTAL IMPURITIES (ICH Q3D), REACTIVE TO ADAPTIVE
Elemental impurities are addressed by the old heavy-metals test, or only when a regulator asks.
A Q3D procedure exists, but assessments apply a single route limit and check the drug substance in isolation.
A documented risk assessment sums all sources against the route-correct PDE, testing only where a source is significant.
Supplier, excipient, and equipment changes are screened for elemental impact; drift signals reopen the assessment.
Elemental control is justified at the source across the formulation, removing unnecessary routine testing by design.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 3
Derived from the 3 standards SPEQ maps to this subject, across 2 regulatory bodies: FDA, ICH.
RECORDS & OBJECTIVE EVIDENCE
- A documented Q3D risk assessment covering API, excipients, water, container-closure, and equipment
- PDE-based limits tied to the finished product's route and maximum daily dose
- Validated ICP-MS/ICP-OES methods where testing is warranted
- Consideration of Class 1 elements (arsenic, cadmium, mercury, lead) in every assessment
- Change-control records reassessing elemental impurities after a supplier or equipment change
COMMON INSPECTION FINDINGS
- An oral-route limit applied to a parenteral product
- The drug substance assessed in isolation without summing excipient and equipment sources
- No documented risk assessment behind the elemental control strategy
- Class 1 elements not considered in the assessment
- A supplier or excipient-grade change not reassessed for elemental impact
From heavy-metals test to toxicological limits
The historical pharmacopeial heavy-metals wet-chemistry test was non-specific, insensitive, and did not correspond to any actual toxicological limit. ICH Q3D replaced that with permitted daily exposures (PDEs) derived from toxicology for each element, expressed in micrograms per day. Because the limit is a daily exposure, the concentration limit in a given product depends on its maximum daily dose, which is why Q3D control is a calculation and a risk assessment rather than a fixed ppm specification.
The framework classifies elements by toxicity and likelihood of occurrence. The highest-concern class (Class 1) includes arsenic, cadmium, mercury and lead, which must be considered in every risk assessment because of their toxicity and ubiquity. Other classes are addressed based on whether they were intentionally added or plausibly present.
Route of administration drives the limit
ICH Q3D sets different PDEs for oral, parenteral and inhalation routes because bioavailability and target-organ exposure differ sharply, and the current revision adds cutaneous/transdermal considerations. Parenteral limits are generally the most stringent and inhalation limits the most conservative for certain elements, so the same drug substance can be acceptable orally and out of specification if reformulated for injection. The risk assessment must therefore be tied to the actual finished-product route and dose.
This is where practitioners most often go wrong: applying an oral-route limit to a parenteral, or assessing the drug substance in isolation without summing contributions from excipients, water, container-closure and manufacturing equipment across the whole formulation. Q3D requires the assessment to consider all potential sources and to sum them against the product PDE.
Building the risk assessment
A compliant Q3D program is a documented risk assessment covering potential elemental sources: intentionally added catalysts and reagents (ICH Q7 process controls are relevant here for drug substance), elemental impurities in excipients and water, extractables and leachables from container-closure and manufacturing equipment, and the drug substance itself. For each element the assessment estimates the likely contribution, sums the sources, and compares the total to the PDE. Where the total is comfortably below a control threshold (commonly taken as 30% of the PDE), routine testing may not be required and the control strategy relies on the assessment.
Where a source is significant or variable, the control strategy adds specifications and testing — typically ICP-MS or ICP-OES as validated methods per the analytical-method lifecycle. SPEQ synthesis: the deliverable regulators expect is the reasoning, not just a certificate of analysis — a Q3D dossier that shows the sources considered, the data or justification used, and the conclusion for each element.
Lifecycle and GMP integration
Elemental-impurities control is not a one-time filing exercise. Changes in supplier, excipient grade, equipment, container-closure or process can change the elemental burden, so Q3D belongs in change control under 21 CFR 211 and in the periodic product quality review. A new excipient supplier with a different mineral profile, or a switch in manufacturing equipment alloy, is a Q3D-relevant change even if it looks quality-neutral otherwise.
The risk assessment should also be revisited when stability or field data suggest drift, and its conclusions must be internally consistent with the specification set. Q3D done well removes unnecessary routine testing by justifying control at the source; done poorly it becomes an untraceable claim that the finished-product test then has to catch.
FREQUENTLY ASKED
Why did ICH Q3D replace the heavy-metals test?
The classical heavy-metals wet-chemistry test was non-specific and insensitive and did not map to any real toxicological limit. ICH Q3D replaced it with permitted daily exposures derived from toxicology for a defined set of elements, differentiated by route of administration, and a risk-based control strategy rather than a single generic test.
Does every element need to be tested in every product?
No. The framework requires a risk assessment of all potential sources; routine testing is warranted only where a source is significant or variable. Class 1 elements (arsenic, cadmium, mercury, lead) must always be considered, but if the summed contribution sits well below the control threshold, the control can rely on the documented assessment rather than release testing.
Why does the route of administration matter so much?
Because Q3D sets different PDEs for oral, parenteral and inhalation (and, in the current revision, cutaneous/transdermal) routes to reflect differing bioavailability and target-organ exposure. A limit acceptable orally can be exceeded for the same material given parenterally, so the assessment must use the finished product's actual route and maximum daily dose.